Table 1 TCF7L2 rs12255372 and risk of breast cancer
From: No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer
N | N | Ordinal OR (95% CI) | Co-Dominant ORs (95% CI) | |||||
|---|---|---|---|---|---|---|---|---|
Cases | Controls | Per T-allele | P (trend) | GT v GG | TT v GG | P (2 d.f.) | ||
Total | --- | 779 | 830 | 1.04 (0.89-1.22) | 0.62 | 1.16 (0.93-1.43) | 0.92 (0.62-1.36) | 0.31 |
Menopausal | Pre | 268 | 213 | 1.28 (0.94-1.75) | 0.12 | 1.51 (1.01-2.26) | 1.21 (0.56-2.61) | 0.14 |
status | Post | 467 | 573 | 0.95 (0.77-1.16) | 0.59 | 1.03 (0.78-1.34) | 0.79 (0.49-1.29) | 0.60 |
BMI | ≤ 25.9 | 341 | 394 | 1.07 (0.84-1.37) | 0.59 | 1.25 (0.90-1.73) | 0.91 (0.50-1.64) | 0.34 |
> 25.9 | 406 | 393 | 1.03 (0.82-1.30) | 0.78 | 1.13 (0.83-1.54) | 0.92 (0.52-1.63) | 0.66 | |
Family | No | 424 | 480 | 1.04 (0.84-1.30) | 0.70 | 1.09 (0.81-1.46) | 1.02 (0.60-1.73) | 0.85 |
history | Yes | 336 | 312 | 0.99 (0.77-1.28) | 0.95 | 1.25 (0.89-1.76) | 0.68 (0.36-1.28) | 0.14 |
Estrogen | Positive | 472 | 830 | 1.09 (0.91-1.31) | 0.34 | 1.16 (0.90-1.49) | 1.10 (0.70-1.71) | 0.50 |
Receptor (ER) | Negative | 107 | 830 | 1.11 (0.81-1.52) | 0.52 | 1.41 (0.92-2.17) | 0.84 (0.36-1.96) | 0.21 |
Progesterone | Positive | 429 | 830 | 1.21 (0.93-1.35) | 0.23 | 1.19 (0.92-1.54) | 1.15 (0.73-1.81) | 0.39 |
Receptor (PR) | Negative | 147 | 830 | 1.00 (0.76-1.32) | 0.99 | 1.19 (0.82-1.71) | 0.74 (0.35-1.56) | 0.40 |
HER2 status | Positive | 122 | 830 | 1.14 (0.83-1.55) | 0.42 | 1.68 (1.12-2.53) | 0.49 (0.17-1.45) | 0.01 |
Negative | 269 | 830 | 1.02 (0.82-1.27) | 0.85 | 1.04 (0.78-1.40) | 1.01 (0.60-1.70) | 0.96 | |
ER, PR, HER2 | All Negative | 51 | 842 | 1.47 (0.95-2.26) | 0.08 | 2.16 (1.16-4.01) | 1.36 (0.43-4.30) | 0.05 |